US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

15.91

+0.24001.53%

Post-market: 15.910.00000.00%17:17 EDT

Volume:1.27M

Turnover:20.00M

Market Cap:1.45B

PE:-26.88

High:16.00

Open:15.77

Low:15.61

Close:15.67

Loading ...

Overview Company News Filings

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

PagerDuty Named a Leader and Outperformer in GigaOm Radar for IT Incident Response Platforms for Third Consecutive Year

Verizon Frontline provides critical Unmanned Aircraft Systems support for New Orleans PD during Mardi Gras

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

ACCESS Newswire

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

PagerDuty (PD) and Uber (UBER), DoorDash (DASH), GameStop (GME), LiveRamp (RAMP) Stocks Trade Down, What You Need To Know

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

PagerDuty (PD) Gets a Buy from Truist Financial

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

PagerDuty Report Finds More Than Half of Companies Have Deployed AI Agents

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":15.91,"timestamp":1746820800000,"preClose":15.67,"halted":0,"volume":1268449,"hourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":15.91,"latestTime":"17:17 EDT","volume":142320,"amount":2264310.94,"timestamp":1746825450570},"delay":0,"floatShares":81793630,"shares":91084454,"eps":-0.591956,"marketStatus":"Market Closed","change":0.24,"latestTime":"05-09 16:00:00 EDT","open":15.77,"high":16,"low":15.61,"amount":20002098.710958,"amplitude":0.024888,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.591956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":15.67,"postHourTrading":{"tag":"盘后","latestPrice":15.91,"preClose":15.91,"latestTime":"17:17 EDT","volume":142320,"amount":2264310.94,"timestamp":1746825450570},"volumeRatio":1.4528509440382893,"impliedVol":0.6099,"impliedVolPercentile":0.784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":81793630,"roa":"-4.03%","roe":"-26.63%","lyrEps":-0.591956,"volumeRatio":1.4528509440382893,"shares":91084454,"dividePrice":0,"high":16,"amplitude":0.024888,"preClose":15.67,"low":15.61,"week52Low":14.295,"pbRate":"11.16","psRate":"3.10","week52High":23.12,"institutionHeld":0,"latestPrice":15.91,"eps":-0.591956,"divideRate":0,"volume":1268449,"delay":0,"ttmEps":-0.591956,"open":15.77,"prevYearClose":18.26,"prevWeekClose":15.47,"prevMonthClose":15.51,"prevQuarterClose":18.27,"fiveDayClose":15.47,"twentyDayClose":15.35,"sixtyDayClose":19.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527415023","title":"Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415023","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415023?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:30","pubTimestamp":1744720200,"startTime":"0","endTime":"0","summary":"Analysis of blood samples from patients treated withAramchol in ARMOR  provides new and important insights into the biochemical and physiological effects of the drug.The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.TEL AVIV, Israel, April 15, 2025 /PRNewswire/ --Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic  blood markers for its lead compound, Aramchol, the industry's most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol's potential far beyond its role in NASH  therapy—offering a deeper understanding of the drug candidate's biochemical impact and presenting an exciting opportunity to enhance clin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/galmed-unveils-novel-pharmacodynamic-blood-123000723.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-unveils-novel-pharmacodynamic-blood-123000723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4157","IE00B19Z4B17.USD","PD","BK4139","AEIS","GLMD","IE00B66KJ199.SGD","BK4023","LU1169589451.USD","LU1169590202.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2527492780","title":"MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492780?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714860,"startTime":"0","endTime":"0","summary":"With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% andMean Weight Loss of 4.3% at Day 26 at 32 mg Dose . Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dLand Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose. Maximum Waist Circumference Reduction of3.9 Inches and Mean Reduction of 1.6 InchesDemonstrates Strong Signal ofGlucagon Efficacy at Day 33 at 32 mg Dose. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. Planned Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose  Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin  an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BMI","LU1169589451.USD","OXM","BK4218","PK","LU1169590202.USD","MTVA","PD","BK4139","BK4157","BK4590","GLP","BK4144","BK4023","BK4202"],"gpt_icon":0},{"id":"2527533581","title":"Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9","url":"https://stock-news.laohu8.com/highlight/detail?id=2527533581","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527533581?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/14/3060774/0/en/Verve-Therapeutics-Announces-Positive-Initial-Data-from-the-Heart-2-Phase-1b-Clinical-Trial-of-VERVE-102-an-In-Vivo-Base-Editing-Medicine-Targeting-PCSK9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1878469433.USD","PD","BK4599","LU1169589451.USD","RNA","BK4585","BK4588","BK4023","VERV","ALT","BK4539","BK4139","LU1169590202.USD"],"gpt_icon":0},{"id":"2526255278","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526255278","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526255278?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282920,"startTime":"0","endTime":"0","summary":"–SRC recommended that the trial escalate to the next dose level of 30mg capsule –。“We are seeing substantial enrollment demand and have already identified Cohort 6 patients. In addition, we continue to observe substantial exposure levels of PAS-004, and remain excited about the possibility of delivering relevant pERK inhibition below the no observed adverse effect levels  as we modeled and observed during our previously conducted nine-month chronic toxicity studies. The on label rash rate for both approved MEKi for NF1 exceeds 80% which leads to patients discontinuing who otherwise should remain on treatment for longer periods of time”, stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “We will provide additional safety, pharmacokinetic  and pharmacodynamic  data over the next several weeks.”This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Ac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-safety-110200309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4139","BK4231","KTTAW","BK4181","CNS","KTTA","IE0031619046.USD","BK4023","BK4157","IE00B66KJ199.SGD","BK4135","BK4007","BK4218","AEIS","LU1169589451.USD","LU1169590202.USD","SRC","IE00B7SZL793.SGD","LENZ","PK","PD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2526517485","title":"Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526517485","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526517485?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:00","pubTimestamp":1744282800,"startTime":"0","endTime":"0","summary":"GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models. Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025. Summary: In animal models of both GBA1 and idiopathic Parkinson’s disease, GT-02287 is able to rescue motor deficits and prevent the development of deficits in complex behaviors such as nesting. These effects persist even following withdrawal of the compound, suggesting a disease-modifying potential of GT-02287. The new preclinical data that were pres","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-presents-additional-preclinical-110000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GT","BK4119","BK4007","LENZ","BK4023","PK","PD","BK4181","BK4218","GANX","LU1169590202.USD","BK4588","BK4585","BK4139","CSF","LU1169589451.USD"],"gpt_icon":0},{"id":"2525416818","title":"PagerDuty Named a Leader and Outperformer in GigaOm Radar for IT Incident Response Platforms for Third Consecutive Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2525416818","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525416818?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:00","pubTimestamp":1744117200,"startTime":"0","endTime":"0","summary":"PagerDuty has been named a Leader and an Outperformer in the 2025 GigaOm Radar for IT Incident Response Platforms.GigaOm report recognizes the PagerDuty Operations Cloud with top three scores in all categories showcasing strengths in incident response management, real-time mobile support and comprehensive AIOps capabilities. Read the full GigaOm Radar for IT Incident Response Platforms and learn more about the PagerDuty Operations Cloud here.PagerDuty ranked among the top three companies in the areas that GigaOm considers differentiating and critical in the sector, including:. Key Features that differentiate solutions, highlighting the primary criteria to be considered when evaluating an IT incident response platform solution. PagerDuty had the highest score of 4.4 out of 5.In a market shaped by rising complexity and the need for operational resilience, GigaOm highlighted numerous strengths of the PagerDuty Operations Cloud, including advanced incident response capabilities, seamless m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-named-leader-outperformer-gigaom-130000100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD"],"gpt_icon":0},{"id":"2525041676","title":"Verizon Frontline provides critical Unmanned Aircraft Systems support for New Orleans PD during Mardi Gras","url":"https://stock-news.laohu8.com/highlight/detail?id=2525041676","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525041676?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:00","pubTimestamp":1744034400,"startTime":"0","endTime":"0","summary":"What you need to know: The Verizon Frontline Crisis Response Team supported the New Orleans Police Department (NOPD) with Unmanned Aircraft Systems (UAS) support during the busiest week of Mardi Gras.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056892/0/en/Verizon-Frontline-provides-critical-Unmanned-Aircraft-Systems-support-for-New-Orleans-PD-during-Mardi-Gras.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0321505439.SGD","IE00BSNM7G36.USD","LU0942090050.USD","BK4581","BK4559","LU1699723380.USD","LU1066051811.HKD","BK4515","LU0306807586.USD","BK4023","LU2384288077.EUR","BK4534","BK4588","LU1066051225.USD","LU1169590202.USD","VZ","LU1621768206.USD","BK4550","LU1059921491.USD","BK4585","LU0306806265.USD","LU1066051498.USD","LU1621767810.EUR","PD","LU1430594728.SGD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","LU1571399168.USD","LU1621768115.EUR","BK4115","LU0868494617.USD","LU1366192091.USD","LU0985481810.HKD","LU1621767737.EUR","LU1162221912.USD","LU0320765646.SGD","BK4533","LU0868494708.USD","LU1169589451.USD","LU1914381329.SGD","LU0098860793.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2525501799","title":"NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525501799","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525501799?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:05","pubTimestamp":1744027500,"startTime":"0","endTime":"0","summary":"Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056692/0/en/NKGen-Biotech-Presents-Data-from-Phase-1-2a-Clinical-Trial-of-Troculeucel-in-Moderate-Alzheimer-s-Disease-at-the-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-AD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2525301085","title":"Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525301085","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525301085?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"- Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2  total and sub-scale scores. - Treatment with CREXONT also resulted in significantly more patients waking up in an \"On\" state compared to immediate-release CD/LD patients, as part of separate study analysis. BRIDGEWATER, N.J., April 07, 2025----Amneal Pharmaceuticals, Inc.  , a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release  carbidopa/levodopa  experienced statistically significant improvements in sleep quality. These improvements were measured by their Parkinson’s Disease Sleep Scale-2  total scores, showing a mean difference of -2.35 .A separate analysis of Hauser diary entries, which is a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN. Treatment w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amneal-announces-data-phase-3-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","BK4178","SG9999001440.SGD","LU1169589451.USD","LU1169590202.USD","AAN","LU1978683503.SGD","IR","CNS","AMRX","BK4161","LU0256863902.USD","CD","BK4007","BK4023","BK4588","BK4585","LU0124384867.USD","BK4116","LU0256863811.USD","LU0417517546.SGD","BK4135"],"gpt_icon":0},{"id":"2525045971","title":"Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2525045971","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525045971?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1  and Vascular Endothelial Growth Factor , and HS3215, a dual-target biologic binding to Human Epidermal Growth Factors 2  and 3  receptors. Using its proprietary EpiClick Technology, a versatile multispecific antibody engineering platform, HS1940 and HS3215 represent a key expansion of Tharimmune's product pipeline and underscores the Company's commitment to addressing unmet needs.HS1940 is designed as a biparatopic  biologic, simultaneously engaging the PD-1 pathway and inhibiting angiogenesis. By using multiple, previously undruggable epitopes on PD-1, and blocking VEGF-mediated tumor vascularization, HS1940 may broaden treatment options and improve outcomes across multiple types of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-data-novel-120000722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4604","BK4139","THAR","PBC","LU1169590202.USD","BK4588","TM","BK4099","BK4585","BK4023","03160","LU1169589451.USD","PD","BK4555"],"gpt_icon":0},{"id":"2524017002","title":"Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2524017002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524017002?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:00","pubTimestamp":1743771600,"startTime":"0","endTime":"0","summary":"Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055960/0/en/Sonnet-s-SON-1010-Demonstrates-a-Strong-Safety-Profile-in-Combination-with-Atezolizumab-for-Treatment-of-Platinum-Resistant-Ovarian-Cancer-Including-a-Partial-Response-at-the-Highe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTD","BK4535","PK","SON","BK4531","01698","SG9999011746.SGD","BK4007","BK4080","BK4526","BK4231","LU1169589451.USD","BK4139","IE00BYTNYN87.SGD","PROC","BK4565","TME","BK4509","LU1093756168.USD","BK4218","BK4136","BK4181","LU1169590202.USD","LU1721428933.USD","PD","BK4585","LU2039709279.SGD","BK4563","BK4588","LU0359201612.USD","LU0359202008.SGD","LU1023057109.AUD","PR","SD","BK4548","BK4567","SRC","BK4571","IE00BYQQ9H92.USD","LU1093756325.SGD","BK4213","BK4121","BK4108","SONN","BK4552","BK4533","IE00BFXG0V08.USD","LU2413666699.HKD","BK4023","IE00B12V2V27.USD"],"gpt_icon":0},{"id":"2524085052","title":"Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524085052","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524085052?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:00","pubTimestamp":1743764400,"startTime":"0","endTime":"0","summary":"–Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055854/0/en/Arvinas-Presents-First-in-Human-Data-for-Investigational-Oral-PROTAC-ARV-102-Demonstrating-Blood-Brain-Barrier-Penetration-and-Central-and-Peripheral-LRRK2-Degradation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1169590202.USD","BK4023","CSF","PSP","PD"],"gpt_icon":0},{"id":"2524999022","title":"PagerDuty (PD) and Uber (UBER), DoorDash (DASH), GameStop (GME), LiveRamp (RAMP) Stocks Trade Down, What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2524999022","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524999022?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:06","pubTimestamp":1743699974,"startTime":"0","endTime":"0","summary":"A number of stocks fell in the after-market session after President Trump announced \"reciprocal tariffs\" on all US imports, set at a minimum rate of 10%.Markets reacted negatively to the announcement, reflecting deep concerns among investors about the broader economic implications. The tariffs were likely seen as a significant threat to global trade flows, with the potential to slow economic growth, drive up consumer prices, and spark retaliatory measures.Wedbush analyst Dan Ives captured the prevailing market anxiety, stating, \"We would characterize this slate of tariffs as 'worse than the worst case scenario' the Street was fearing.\" His comment highlighted how the scope and severity of the tariffs far exceeded Wall Street's expectations, adding a new layer of uncertainty for businesses and investors.The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.Cloud Monitoring company PagerDuty  fell 17.4%. Is now the time to buy ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-pd-uber-uber-doordash-170614086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1064131342.USD","LU1316542783.SGD","IE00BFMHRM44.USD","LU0006306889.USD","LU1814569148.SGD","LU0353189680.USD","UBER","BK4577","LU1861214812.USD","SG9999014906.USD","SG9999014880.SGD","SG9999015978.USD","BK4505","BK4549","LU0106261612.USD","RAMP","SG9999014898.SGD","IE00BZ199S13.USD","LU0127658192.USD","IE00B19Z3B42.SGD","LU2065171402.SGD","PD","BK4548","LU0240878834.USD","SG9999014914.USD","BK4503","SG9999018857.SGD","LU0642271901.SGD","LU1169590202.USD","BK4076","GME","SG9999015952.SGD","BK4023","LU1861219969.SGD","BK4551","DASH","BK4122","GB00BDT5M118.USD","LU0205193047.USD","SG9999015945.SGD","LU0719512351.SGD","BK4209","SG9999018865.SGD","LU2065171311.SGD","SG9999015986.USD","LU0106261372.USD","BK4022","IE0002270589.USD","BK4535","SGXZ31699556.SGD"],"gpt_icon":1},{"id":"2524598032","title":"Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524598032","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524598032?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health. Increases insurance coverage to over 50% of covered lives. This expanded coverage increases CREXONT’s total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%. The Company had initially set a goal to surpass 50% coverage by the end of 2025, making this milestone—achieved nine months ahead of schedule—a testament to Amneal’s commitment to broadening patient access. The VA has already added the product in its national formulary, covering approximately 10% of U.S. PD patients. UnitedHealthcare will add CREXONT to its standard prescription drug lists in the second quarter of 2025. In addition, CVS Health will add CREXONT as a \"preferred\" product to its national formulary on July 1, 2025.More \"Good On\" time with less frequent dosing: A head-to-head clinical trial showed CREXONT provides more \"Good On\" time per day, and 1.55 more hours of \"Good On\" time","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amneal-announces-expanded-coverage-crexont-120000502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0256863902.USD","AMRX","LU0417517546.SGD","PD","SG9999001440.SGD","LU1978683503.SGD","BK4585","BK4023","LU0256863811.USD","LU1169589451.USD","BK4588","LU0124384867.USD","LU1169590202.USD","IR","BK4007","BK4161"],"gpt_icon":0},{"id":"2524461304","title":"PagerDuty (PD) Gets a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461304?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:17","pubTimestamp":1743592659,"startTime":"0","endTime":"0","summary":"In a report released today, Joel Fishbein from Truist Financial reiterated a Buy rating on PagerDuty (PD – Research Report). The company’s shares c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pagerduty-pd-gets-a-buy-from-truist-financial-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pagerduty-pd-gets-a-buy-from-truist-financial-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1169590202.USD","PD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2524940495","title":"Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524940495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524940495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes  and Clinical Global Impression of Change . Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory. “The presentation of the Extension phase data at AD/PD 2025 is an opportunity to share our findings and engage deeply with the DLB medical community as we plan for pivotal development and work to bring neflamapimod to patients as rapidly as possible,” said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. “The positive findings across the primary outcome measure and multiple additional clinically important endpoints evaluated in the first 16 weeks of the Extension phase strengthen our b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigators-present-clinical-trial-results-110000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DLB","LU0345774631.USD","LU0345774391.USD","LU0348723411.USD","CRVO","LU0240878834.USD","BK4023","CGIC","LU1169589451.USD","LU1169590202.USD","PD","LU0205193047.USD","BK4139","LU0240877869.USD","LU0205194284.USD","TUG","BK4097"],"gpt_icon":0},{"id":"2524618914","title":"Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524618914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524618914?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 -- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease  -. WATERTOWN, Mass., April 02, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases being held April 1 – April 5 in Vienna, Austria.Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s DiseaseDate and Time: Wednesday, April 2, 2025, 3:20 PM – 3:35 PM Session: TREM2, Microglia: From Mechanisms to Potenti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-presents-data-small-110000638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4081","VIGL","LU1169589451.USD","PK","CSF","BK4218","BK4181","CET","LU1169590202.USD","PAM","ARIA","PD","VG","BK4023","BK4563","BK4213","BK4139"],"gpt_icon":0},{"id":"2524468300","title":"AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524468300","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524468300?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:00","pubTimestamp":1743588000,"startTime":"0","endTime":"0","summary":"AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease. Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein  antibody levels on average over 20-fold higher than placebo after 4 immunizations. Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titers. ACI-7104.056 is well tolerated with no safety issues reported to date. Lausanne, Switzerland, April 2, 2025 – AC Immune SA , a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein  active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease .Interim results show positive antibody responses were effect","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ac-immune-reports-further-positive-100000259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACI","BK4139","LU1169590202.USD","LU1169589451.USD","ACIU","BK4113","BK4135","PD","AC","BK4023"],"gpt_icon":0},{"id":"2524124280","title":"PagerDuty Report Finds More Than Half of Companies Have Deployed AI Agents","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124280","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124280?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:30","pubTimestamp":1743539400,"startTime":"0","endTime":"0","summary":"By 2027, 86% of companies expect to be operational with AI agents.Executives anticipate agentic AI will have faster adoption and higher ROI than generative AI, with 62% expecting returns above 100%. Leaders expect nearly 40% of work to be automated or expedited with the help of AI agents. To read the full report, including survey findings and methodology, please visit here.The adoption of GenAI has surged, with McKinsey & Company reporting usage in at least one business function rising from 33% in 2023 to 71% by July 2024. Now, agentic AI adoption is poised to accelerate even faster while reshaping automation and decision-making across industries. Companies are no longer just experimenting. The latest PagerDuty survey data shows that 94% of companies believe they will adopt agentic AI more quickly than GenAI, with 55% strongly agreeing that they will integrate it across their organizations at an accelerated pace. As businesses look to automate complex workflows and drive efficiency, ag","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pagerduty-report-finds-more-half-203000686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2524113865","title":"Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524113865","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524113865?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":"Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053340/0/en/Cerevance-Presents-Topline-Results-from-Phase-2-ASCEND-Trial-of-Solengepras-as-Monotherapy-Treatment-for-Early-Stage-Parkinson-s-Disease-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169590202.USD","SSI","BK4585","ESS","BK4588","PD","LU1169589451.USD","BK4597","BK4215"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2024-09-03","symbol":"PD","fiscalQuarterEnding":"2024/07","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-05-30","symbol":"PD","fiscalQuarterEnding":"2024/04","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1717041600000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2024-03-14","symbol":"PD","fiscalQuarterEnding":"2024/01","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0769,"buy":0.3077,"hold":0.4615,"sell":0.1538,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4615,"analysts":13,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2025-05-08","current":-25.606004,"percent":0.475993,"low":-81.051795,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"high":-13.794086,"avg":-30.583304,"sd":13.45012,"marketCap":1394502990},"quantilePoints":[{"date":"2020-05-15","current":-40.070276,"twenty":-76.181489,"median":-42.907111,"eighty":-35.799269,"marketCap":2017097635},{"date":"2020-05-22","current":-43.435432,"twenty":-76.082732,"median":-42.504512,"eighty":-36.303053,"marketCap":2186496193},{"date":"2020-05-29","current":-41.363368,"twenty":-75.845714,"median":-42.329073,"eighty":-36.388531,"marketCap":2082190599},{"date":"2020-06-05","current":-41.572682,"twenty":-75.735317,"median":-42.449993,"eighty":-36.532943,"marketCap":2067575752},{"date":"2020-06-12","current":-39.198908,"twenty":-75.187331,"median":-42.329073,"eighty":-36.817602,"marketCap":1949518515},{"date":"2020-06-19","current":-48.393323,"twenty":-74.002242,"median":-42.496137,"eighty":-36.834452,"marketCap":2406793548},{"date":"2020-06-26","current":-46.067026,"twenty":-73.969323,"median":-42.888728,"eighty":-36.850607,"marketCap":2291097455},{"date":"2020-07-02","current":-47.49129,"twenty":-73.92982,"median":-42.964871,"eighty":-36.863809,"marketCap":2361931798},{"date":"2020-07-10","current":-44.658587,"twenty":-72.98504,"median":-43.055636,"eighty":-36.906716,"marketCap":2221050161},{"date":"2020-07-17","current":-40.765599,"twenty":-72.685476,"median":-42.964871,"eighty":-36.931288,"marketCap":2027436292},{"date":"2020-07-24","current":-42.807044,"twenty":-72.640646,"median":-42.989625,"eighty":-37.118318,"marketCap":2128965516},{"date":"2020-07-31","current":-48.235072,"twenty":-72.530247,"median":-43.175427,"eighty":-37.208604,"marketCap":2398923066},{"date":"2020-08-07","current":-47.238087,"twenty":-72.318638,"median":-43.360924,"eighty":-37.407321,"marketCap":2349339026},{"date":"2020-08-14","current":-46.177802,"twenty":-72.098738,"median":-43.468321,"eighty":-37.467623,"marketCap":2296606793},{"date":"2020-08-21","current":-45.95625,"twenty":-71.69039,"median":-43.550826,"eighty":-37.518859,"marketCap":2285588118},{"date":"2020-08-28","current":-48.583225,"twenty":-71.41486,"median":-43.699242,"eighty":-37.630539,"marketCap":2416238127},{"date":"2020-09-04","current":-38.528058,"twenty":-71.368789,"median":-43.748751,"eighty":-37.658486,"marketCap":1997756875},{"date":"2020-09-11","current":-36.766338,"twenty":-71.24954,"median":-43.637964,"eighty":-37.464273,"marketCap":1906408152},{"date":"2020-09-18","current":-38.03784,"twenty":-70.931543,"median":-43.525964,"eighty":-37.424178,"marketCap":1972338100},{"date":"2020-09-25","current":-40.596165,"twenty":-70.750862,"median":-43.369188,"eighty":-37.464273,"marketCap":2104992334},{"date":"2020-10-02","current":-42.378825,"twenty":-69.760733,"median":-43.304333,"eighty":-37.506887,"marketCap":2197426830},{"date":"2020-10-09","current":-45.308378,"twenty":-68.893466,"median":-43.360924,"eighty":-37.540906,"marketCap":2349330024},{"date":"2020-10-16","current":-46.719472,"twenty":-68.681421,"median":-43.459295,"eighty":-37.566006,"marketCap":2422498055},{"date":"2020-10-23","current":-44.664183,"twenty":-67.026675,"median":-43.550718,"eighty":-37.624584,"marketCap":2315927228},{"date":"2020-10-30","current":-41.565912,"twenty":-65.321463,"median":-43.550772,"eighty":-37.657731,"marketCap":2155275682},{"date":"2020-11-06","current":-46.121291,"twenty":-64.742086,"median":-43.550826,"eighty":-37.676934,"marketCap":2391481172},{"date":"2020-11-13","current":-46.35136,"twenty":-63.787431,"median":-43.643849,"eighty":-37.728931,"marketCap":2403410742},{"date":"2020-11-20","current":-47.79313,"twenty":-62.855819,"median":-43.781756,"eighty":-37.757248,"marketCap":2478169382},{"date":"2020-11-27","current":-52.440537,"twenty":-62.329113,"median":-43.973974,"eighty":-37.811067,"marketCap":2719146700},{"date":"2020-12-04","current":-58.503982,"twenty":-61.897872,"median":-44.116471,"eighty":-37.910083,"marketCap":3346135266},{"date":"2020-12-11","current":-61.956348,"twenty":-61.897872,"median":-44.23472,"eighty":-37.979009,"marketCap":3543593297},{"date":"2020-12-18","current":-64.76408,"twenty":-63.261641,"median":-44.342085,"eighty":-38.134161,"marketCap":3704181571},{"date":"2020-12-24","current":-65.981719,"twenty":-64.468982,"median":-44.366057,"eighty":-38.286785,"marketCap":3773824445},{"date":"2020-12-31","current":-59.735947,"twenty":-64.377301,"median":-44.622066,"eighty":-38.319351,"marketCap":3416597468},{"date":"2021-01-08","current":-63.775644,"twenty":-64.248374,"median":-44.664183,"eighty":-38.342002,"marketCap":3647647944},{"date":"2021-01-15","current":-65.265461,"twenty":-64.491902,"median":-44.85652,"eighty":-38.342002,"marketCap":3732858049},{"date":"2021-01-22","current":-70.007091,"twenty":-64.924465,"median":-44.940871,"eighty":-38.368803,"marketCap":4004055593},{"date":"2021-01-29","current":-69.806539,"twenty":-66.010369,"median":-45.124322,"eighty":-38.447577,"marketCap":3992585002},{"date":"2021-02-05","current":-78.774094,"twenty":-67.606194,"median":-45.279297,"eighty":-38.515566,"marketCap":4505484287},{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-08","current":-25.606004,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1394502990}],"updateTime":1746856852499}}}